Cadila, Cipla step up investments for improved drug quality

Includes regular visits, interactions with workers on shop floor by members of senior management

Drug makers including Cadila Healthcare and Cipla are investing in automation to enhance quality compliance and monitor deviations in manufacturing processes.

Investment in automation is one of the step undertaken by Indian companies who have come under the scanner of overseas drug regulators. Violations in good manufacturing practices have resulted in warning letters and delayed product approvals for Indian companies. To overcome this pharma companies are investing in both technology and staff training.

"We have invested around Rs 450 crore in automation and technology improvements. We have introduced laboratory information management system and a software which tracks deviations